Mekonos is an enabling technology company transforming synthetic biology and personalized medicine. The company's SoC merges innovations in MEMS, microfluidics, and chemistry for controlled and individualized molecular delivery in cells at scale. The company is headquartered in San Francisco, is backed by leading investors in both healthcare and technology, and is an alum of Berkeley Launch, Berkeley SkyDeck, Creative Destruction Lab, and named a 2018 Fierce 15 startup.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 11/09/21 | $25,000,000 | Series A |
Debiopharm Elementum Ventures Fiscus Ventures  Novartis Pharma AG Peak6 Investments Reimagined Ventures Sands Capital Section 32 TDK Ventures | undisclosed |
